Background: Several randomised controlled trials (RCTs) have investigated the usefulness of pituitary block with gonadotrophin-releasing hormone (GnRH) antagonists during intrauterine insemination (IUI) cycles, with conflicting results.

Objective: The aim of the present systematic review and meta-analysis of RCTs was to evaluate the effectiveness of GnRH antagonist administration as an intervention to improve the success of IUI cycles.

Search Strategy: Electronic databases (MEDLINE, Scopus, EMBASE, Sciencedirect) and clinical registers were searched from their inception until October 2017.

Selection Criteria: Randomised controlled trials of infertile women undergoing one or more IUI stimulated cycles with GnRH antagonists compared with a control group.

Data Collection And Analysis: The primary outcomes were ongoing pregnancy/live birth rate (OPR/LBR) and clinical pregnancy rate (CPR). Pooled results were expressed as odds ratio (OR) or mean differences with 95% confidence interval (95% CI). Sources of heterogeneity were investigated through sensitivity and subgroups analysis. The body of evidence was rated using GRADE methodology. Publication bias was assessed with funnel plot, Begg's and Egger's tests.

Main Results: Fifteen RCTs were included (3253 IUI cycles, 2345 participants). No differences in OPR/LBR (OR 1.14, 95% CI 0.82-1.57, P = 0.44) and CPR (OR 1.28, 95% CI 0.97-1.69, P = 0.08) were found. Sensitivity and subgroup analyses did not provide statistical changes in pooled results. The body of evidence was rated as low (GRADE 2/4). No publication bias was detected.

Conclusion: Pituitary block with GnRH antagonists does not improve OPR/LBR and CPR in women undergoing IUI cycles.

Tweetable Abstract: Pituitary block with GnRH antagonists does not improve the success of IUI cycles.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.15269DOI Listing

Publication Analysis

Top Keywords

pituitary block
16
gnrh antagonists
16
randomised controlled
12
controlled trials
12
iui cycles
12
block gonadotrophin-releasing
8
gonadotrophin-releasing hormone
8
intrauterine insemination
8
systematic review
8
review meta-analysis
8

Similar Publications

Forty years of seasonal affective disorder.

Psychiatr Pol

October 2024

Uniwersytet Medyczny w Poznaniu.

In 2024, we observe the fortieth anniversary of the publication, where, for the first time, the term of Seasonal Affective Disorder (SAD) was used. Presently, SAD is regarded as a special category of mood disorder. In the American Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V), the seasonality makes a specifier, "with seasonal pattern", both for recurrent depression or Major Depressive Disorder (MDD), and for Bipolar Disorder (BD).

View Article and Find Full Text PDF

and miRNA regulate mammalian pubertal initiation and Gonadotropin-releasing hormone (GnRH) production. However, it remains unclear which signaling pathways regulates to modulate GnRH production. In this study, the mRNA expression levels of and in the pubertal and juvenile goat hypothalamus and pituitary gland were detected, and expression in the pubertal hypothalamus decreased significantly compared with that in juvenile tissues.

View Article and Find Full Text PDF

Objectives:  Plasma rich in growth factors (PRGF) is presumed to be able to stimulate the regeneration of skin and periodontal tissue. This effect can be attributed to the fact that PRGF contains fewer leukocyte-derived interleukins in comparison to platelet-rich plasma (PRP). However, a comparison of the effects of PRGF and PRP on gingival epithelial cells has not been conducted yet.

View Article and Find Full Text PDF

Invasiveness of pituitary adenoma is the main cause of its poor prognosis, mechanism of which remains largely unknown. In this study, the differential proteins between invasive and non-invasive pituitary tumors (IPA and NIPA) were identified by TMT labeled quantitative proteomics. The differential metabolites in venous bloods from patients with IPA and NIPA were analyzed by untargeted metabolomics.

View Article and Find Full Text PDF

Background And Purpose: Pituitary adenylate cyclase activating polypeptide (PACAP) is a human migraine trigger that is being targeted for migraine. The δ-opioid receptor (δ-receptor) is a novel target for the treatment of migraine, but its mechanism remains unclear. The goals of this study were to develop a mouse PACAP-headache model using clinically significant doses of PACAP; determine the effects of δ-receptor activation in this model; and investigate the co-expression of δ-receptors, PACAP and PACAP-PAC1 receptor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!